HUTCHMED (China) (HMDCF) EBT Margin (2015 - 2021)

HUTCHMED (China)'s (HMDCF) quarterly EBT Margin came in at 172.21% in Q4 2021, down 150.71% quarter-over-quarter from 339.61% in Q3 2021.

Analysis

HUTCHMED (China) (HMDCF) EBT Margin (2015 - 2021) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported EBT Margin for 6 consecutive years, with 172.21% the latest figure, recorded in Q4 2021.

On a quarterly basis, EBT Margin changed N/A year-over-year to 172.21% in Q4 2021; TTM through Dec 2021 was 60.58%, a N/A change from a year earlier, with the FY2025 full-year figure at 90.92%, up 9109.0% from the prior year.
EBT Margin was 172.21% for Q4 2021 at HUTCHMED (China), down from 339.61% in the prior quarter.
Over five years, EBT Margin peaked at 339.61% in Q3 2021 and troughed at 206.3% in Q2 2019.
A 4-year average of 19.04% and a median of 65.16% in 2019 frame the typical range for EBT Margin.
Across the five-year window, EBT Margin slumped 35547 bps in 2019 and jumped 12430 bps in 2020, its largest moves.
Over 4 years, EBT Margin stood at 43.42% in 2018, then plunged by 266 bps to 72.11% in 2019, then dropped by 14 bps to 82.0% in 2020, then tumbled by 110 bps to 172.21% in 2021.
The last three EBT Margin figures came in at 172.21% (Q4 2021), 339.61% (Q3 2021), and 102.29% (Q2 2021), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Amgen	211.50 Bn	197.51 Bn	7.24 Bn	27.53%
2	Gilead Sciences	181.29 Bn	178.11 Bn	6.22 Bn	-131.41%
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn	41.75%
4	Regeneron Pharmaceuticals	82.55 Bn	74.56 Bn	3.93 Bn	35.61%
5	Argenx Se	61.65 Bn	56.47 Bn	1.37 Bn	35.78%
6	Moderna	54.65 Bn	49.52 Bn	52.00 Mn	-528.97%
7	Alnylam Pharmaceuticals	34.18 Bn	30.87 Bn	992.69 Mn	13.77%
8	Biogen	31.36 Bn	30.07 Bn	1.96 Bn	4.84%
9	Roivant Sciences	30.01 Bn	30.01 Bn	1.16 Mn	-20,427.46%
10	HUTCHMED (China)	376.85 Mn	391.04 Mn	-	-

Historic Data

Download Data